Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer

J Clin Oncol. 2025 Feb 10;43(5):487-491. doi: 10.1200/JCO.24.01080. Epub 2024 Oct 9.

¹ Duke Cancer Institute, Duke University, Durham, NC.
² Dana-Farber Cancer Institute, Boston, MA.
³ Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
⁴ Breast Center, Department of OB&GYN and CCC Munich, LMU University Hospital, Munich, Germany.
⁵ European Institute of Oncology, IRCCS, Milan, Italy.
⁶ Jules Bordet Institut, Hôpital Universitaire de Bruxelles, HUB, Brussels, Belgium.
⁷ Breast International Group, Brussels, Belgium.
⁸ Yale Cancer Center, Yale School of Medicine, New Haven, CT.
⁹ University of Alabama at Birmingham, Birmingham, AL.
¹⁰ Breast Cancer Trials (Australia & New Zealand), Melbourne, Australia.
¹¹ Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
¹² Winship Cancer Institute at Emory University, Atlanta, GA.
¹³ The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
¹⁴ Cancer Trials Ireland, Dublin, Ireland.

Abstract

Harmonized global collaborations are crucial to improving outcomes in hormone sensitive operable breast cancer.